Tenaya Therapeutics Inc (TNYA) - News Archive

Tenaya Therapeutics Nets $52.5 Million in Public Offering Amid Anticipated TN-201 Gene Therapy Trial ResultsIn an important development within the biotechnology sector, Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinic...

Tenaya Therapeutics, a clinical-stage biotechnology company, is poised to make a significant announcement regarding its ongoing efforts to address hypertrophic cardiomyopathy (HCM) a genetic heart condition that leads t...

Tenaya Therapeutics (NASDAQ: TNYA), a pioneering biotechnology company focusing on gene therapy and heart-related conditions, has announced the commencement of the RIDGE-1 Phase 1b clinical trial with the dosing of the...

Tenaya Therapeutics Announces Inducement Grants Amidst Strategic Reorganization to Drive Future GrowthIn a bid to solidify its position as a leader in developing innovative therapies for heart disease, Tenaya Therapeuti...

Tenaya Therapeutics Announces Research Leadership UpdatesTenaya Therapeutics, a leading biotechnology company focused on developing treatments for heart diseases, recently made significant changes to its research leader...

Engineering the Future of Precision Heart Medicines: Tenaya Therapeutics Continued Innovation in Capsid Engineering, Gene Editing, and ManufacturingIn the pursuit of developing innovative medicines, scientific advanceme...

In recent years, heart failure with preserved ejection fraction (HFpEF) has emerged as a significant health challenge, with limited treatment options available. However, a recent publication in Nature Communications by...

Tenaya Therapeutics Announces Successful Pricing of Underwritten Offering, Garnering Significant Investment InterestSouth San Francisco-based biotechnology company, Tenaya Therapeutics, made a significant announcement t...